<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-12-02015</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003088</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biotechnology</subject><subj-group><subject>Drug discovery</subject></subj-group></subj-group><subj-group><subject>Computational biology</subject><subj-group><subject>Sequence analysis</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Antigen processing and recognition</subject><subject>Major histocompatibility complex</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry</subject><subj-group><subject>Medicinal chemistry</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Computer science</subject><subj-group><subject>Computer applications</subject><subj-group><subject>Computer-aided design</subject></subj-group></subj-group><subj-group><subject>Computer modeling</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Scrutinizing MHC-I Binding Peptides and Their Limits of Variation</article-title>
<alt-title alt-title-type="running-head">Scrutinizing MHC-I Binding Peptides</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Koch</surname><given-names>Christian P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Perna</surname><given-names>Anna M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pillong</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Todoroff</surname><given-names>Nickolay K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wrede</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Folkers</surname><given-names>Gerd</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hiss</surname><given-names>Jan A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Schneider</surname><given-names>Gisbert</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Zürich, Switzerland</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Charite-Universitätsmedizin Berlin, Molekularbiologie und Bioinformatik, Berlin, Germany</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Briggs</surname><given-names>James M.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Houston, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">gisbert.schneider@pharma.ethz.ch</email></corresp>
<fn fn-type="conflict"><p>I have read the journal's policy and have the following conflicts: GS acts as a scientific consultant to pharmaceutical industry and is a co-founder of inSili.com LLC, Zürich, and AlloCyte Pharmaceuticals Ltd, Basel. The authors have declared that no other competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: PW GF JAH GS. Performed the experiments: CPK AMP MP NKT. Analyzed the data: CPK AMP MP PW GF JAH GS. Contributed reagents/materials/analysis tools: MP NKT. Wrote the paper: CPK AMP GS. Designed and set-up the software server used in analysis: CPK NKT GS.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>6</month><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>6</day><month>6</month><year>2013</year></pub-date>
<volume>9</volume>
<issue>6</issue>
<elocation-id>e1003088</elocation-id>
<history>
<date date-type="received"><day>22</day><month>12</month><year>2012</year></date>
<date date-type="accepted"><day>23</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Koch et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>Designed peptides that bind to major histocompatibility protein I (MHC-I) allomorphs bear the promise of representing epitopes that stimulate a desired immune response. A rigorous bioinformatical exploration of sequence patterns hidden in peptides that bind to the mouse MHC-I allomorph H-2K<sup>b</sup> is presented. We exemplify and validate these motif findings by systematically dissecting the epitope SIINFEKL and analyzing the resulting fragments for their binding potential to H-2K<sup>b</sup> in a thermal denaturation assay. The results demonstrate that only fragments exclusively retaining the carboxy- or amino-terminus of the reference peptide exhibit significant binding potential, with the N-terminal pentapeptide SIINF as shortest ligand. This study demonstrates that sophisticated machine-learning algorithms excel at extracting fine-grained patterns from peptide sequence data and predicting MHC-I binding peptides, thereby considerably extending existing linear prediction models and providing a fresh view on the computer-based molecular design of future synthetic vaccines. The server for prediction is available at <ext-link ext-link-type="uri" xlink:href="http://modlab-cadd.ethz.ch" xlink:type="simple">http://modlab-cadd.ethz.ch</ext-link> (SLiDER tool, MHC-I version 2012).</p>
</abstract>
<abstract abstract-type="summary"><title>Author Summary</title>
<p>Future success in vaccine development will critically depend on identifying potent epitopes with reduced side effects. Among such candidate molecules, immunogenic peptides binding to major histocompatibility protein I (MHC-I) represent a preferred class of biomolecules for vaccine design. Computational models assist in the selection of the best candidate peptides by providing a mathematical rationale for antigen recognition by MHC-I. Here we present a machine-learning model that was trained on recognizing features of known MHC-I binding and non-binding peptide sequences with sustained accuracy. We were able to biochemically validate the computational predictions in a direct binding assay measuring complex formation between synthesized candidate peptides and MHC-I. Strong correspondence between the predictions and the experimentally determined binding potential corroborate the machine-learning model as viable for future antigen design. Thus, our study provides a concept for rapidly finding innovative MHC-I binding peptides with limited experimental effort.</p>
</abstract>
<funding-group><funding-statement>This research was supported by the ETH Zürich and the Swiss National Science Foundation (SNF, grant 205321-134783 to GS). PW was supported by the Deutsche Forschungsgemeinschaft (DFG, SFB 852). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Artificial induction of immunity (immunization) is achieved by priming the immune system with a specific antigen (epitope) bearing the potential of activating the adaptive immune response <xref ref-type="bibr" rid="pcbi.1003088-Murphy1">[1]</xref>. Vaccines are often synchronously administered with adjuvants aiming at boosting the adaptive immune system by activation of the innate immune system through pattern recognition receptors <xref ref-type="bibr" rid="pcbi.1003088-Pashine1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Schijns1">[3]</xref>. Aside from introducing excessive non immune-stimulating pathogenic material into the patient, drawbacks of all clinically applied vaccines include poor or incomplete inactivation, reversion of virulence and limitation to viral pathogens <xref ref-type="bibr" rid="pcbi.1003088-Clem1">[4]</xref>. Utilizing synthetic peptides as antigen mimetics bear the promise to avert some of these effects <xref ref-type="bibr" rid="pcbi.1003088-Moisa1">[5]</xref>–<xref ref-type="bibr" rid="pcbi.1003088-Sesardic1">[7]</xref>. The importance of prediction and design of major histocompatibility protein I (MHC-I) bound peptides that are recognized as a complex by receptors on cytotoxic T cells (cell-mediated immunity) was outlined by Rammensee and co-workers in 1993, who defined canonical sequence motifs for a set of MHC-I alleles (<xref ref-type="fig" rid="pcbi-1003088-g001">Fig. 1</xref>) <xref ref-type="bibr" rid="pcbi.1003088-Rammensee1">[8]</xref>–<xref ref-type="bibr" rid="pcbi.1003088-Rammensee3">[10]</xref>. Residue patterns emerged from a statistical assessment of the frequency and effects of certain amino acids at specified epitope positions. In the subsequent two decades, several prediction models were established for various MHC-I alleles from different organisms, taking into account not only isolated residue positions and their amino acid occupancy but also their positional correlation <xref ref-type="bibr" rid="pcbi.1003088-Peters1">[11]</xref>. Maximizing the predictive accuracy of these models by using modern machine-learning approaches such as cascaded <xref ref-type="bibr" rid="pcbi.1003088-Hiss1">[12]</xref> or deep-learning <xref ref-type="bibr" rid="pcbi.1003088-Bengio1">[13]</xref> architectures bears the chance of increasing the probability of successfully designing synthetic epitopes, acknowledging that MHC-I binding potential poses a necessary prerequisite yet not a guarantee for inducing an immune response.</p>
<fig id="pcbi-1003088-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g001</object-id><label>Figure 1</label><caption>
<title>Volume representation of the MHC H-2K<sup>b</sup> peptide binding cleft derived from a crystal structure model (PDB-ID <xref ref-type="bibr" rid="pcbi.1003088-Berman1">[<bold>63</bold>]</xref>: 1vac <xref ref-type="bibr" rid="pcbi.1003088-Fremont1">[<bold>64</bold>]</xref>) with the protein-bound epitope SIINFEKL.</title>
<p>Numbers within dashed boxes correspond to sequence positions in the respective epitope. Red boxes and associated amino acid codes indicate anchor positions and preferred amino acid composition respectively. The yellow box indicates the secondary anchor at position 3, according to the H-2K<sup>b</sup> canonical sequence motif.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g001" position="float" xlink:type="simple"/></fig>
<p>In this study we developed a cascaded machine learning approach to learn patterns from the available MHC-I binding information in the Immune Epitope Database (IEDB) <xref ref-type="bibr" rid="pcbi.1003088-Vita1">[14]</xref> regarding the murine H-2K<sup>b</sup> allele. We selected this allele and binding octapeptides due to the allele's character as reference model and data availability. Using our new predictive model, we investigated the sequence variability of the well-studied ovalbumin-derived epitope SIINFEKL <xref ref-type="bibr" rid="pcbi.1003088-Rtzschke1">[15]</xref>. We scrutinized octapeptides containing SIINFEKL fragments, while actual fragments were, in contrast to earlier surface plasmon resonance studies <xref ref-type="bibr" rid="pcbi.1003088-Khilko1">[16]</xref> or fluorescence labeling <xref ref-type="bibr" rid="pcbi.1003088-Rtzschke1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Ddier1">[17]</xref>, tested in a thermal denaturation assay <xref ref-type="bibr" rid="pcbi.1003088-Senisterra1">[18]</xref> for their direct binding potential to an H-2K<sup>b</sup>/IgG fusion protein. Formerly understood patterns of epitope binding to the H-2K<sup>b</sup> allele were described in form of Rammensee's statistically derived canonical sequence motif (<xref ref-type="fig" rid="pcbi-1003088-g001">Fig. 1</xref>) <xref ref-type="bibr" rid="pcbi.1003088-Rammensee1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Rammensee2">[9]</xref>, which consists of a tyrosine or phenylalanine residue at position 5 and an aliphatic amino acid at position 8 as so-called ‘main anchors’ as well as a tyrosine at position 3 as ‘secondary anchor’: (3[Y]-5[Y,F]-8[L,M,I,V]). As a result of our study this generic concept was substantially extended with our machine-learning model and validated with rapid direct-binding experiments, which ideally complement strenuous and resource-intensive cell-based assays <xref ref-type="bibr" rid="pcbi.1003088-Udaka1">[19]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Khan1">[20]</xref>. In contrast to the utilization of peptide libraries, the computational approach offers a comprehensive alternative for the analysis of epitope binding motifs with minimal experimental effort involved, thereby additionally focusing on varying fragment lengths and related requirements for binding.</p>
</sec><sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Cascaded machine-learning model</title>
<p>We extracted peptide data from version 7/2012 of the IEDB <xref ref-type="bibr" rid="pcbi.1003088-Vita1">[14]</xref> to train an ensemble machine-learning model utilizing a cascaded architecture. After selecting octapeptides with binding information on the mouse H-2K<sup>b</sup> allele (<xref ref-type="fig" rid="pcbi-1003088-g002">Fig. 2</xref>), a filter was applied draining ambiguous entries resulting in a core set of 1,162 peptides. Binders and non-binders were approximately balanced in this core data set (636 binders, 526 non-binders). We considered these sequence data as diverse due to the abundance of canonical motif complying and non-complying samples. Thus, the observation of often misleading performance estimates due to training data redundancy perceived in a study for MHC-II binding site prediction should not apply to our model <xref ref-type="bibr" rid="pcbi.1003088-ElManzalawy1">[21]</xref>.</p>
<fig id="pcbi-1003088-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g002</object-id><label>Figure 2</label><caption>
<title>Training data derivation.</title>
<p>The Immune Epitope Database (IEDB) served as data source <xref ref-type="bibr" rid="pcbi.1003088-Vita1">[14]</xref>. The murine H-2K<sup>b</sup> allele and a length of eight were selected due to good data availability and reference model character. The core set exhibits similar contributions of positive (636) and negative (526) examples, while redundant ambiguous entries were removed. The core set contained binders and non-binders partially, fully and not agreeing with the canonical sequence motif.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g002" position="float" xlink:type="simple"/></fig>
<p>The core training set was split into a 10-fold cross-validation set and an external validation set by a ratio of 4∶1 in order to retain two evaluation scenarios (<xref ref-type="fig" rid="pcbi-1003088-g003">Fig. 3</xref>) <xref ref-type="bibr" rid="pcbi.1003088-Tropsha1">[22]</xref>. Six amino acid descriptors, namely AAFREQ, BINAATYPE, BINPEP, PEPCATS, PPCA and PPCALI were calculated for every respective training fold. Two classifier models, multilayer Perceptron artificial neural networks <xref ref-type="bibr" rid="pcbi.1003088-Gallinari1">[23]</xref> (ANN) and support vector machines <xref ref-type="bibr" rid="pcbi.1003088-Cortes1">[24]</xref> (SVM), were utilized for auto-parameterized first stage training resulting in a total of 6×2 = 12 first stage models (base classifiers) for every respective evaluation fold. All first stage models were subjected to implicit parameterization employing a grid-based five-fold cross-validation approach during training, utilizing online backpropagation of errors for ANNs <xref ref-type="bibr" rid="pcbi.1003088-Rumelhart1">[25]</xref> and a SMO-type <xref ref-type="bibr" rid="pcbi.1003088-Platt1">[26]</xref> decomposition method for SVMs as training algorithms. ANNs were parameterized with respect to the number of neurons <italic>h</italic> ∈ [2,10] in the hidden layer, the learning rate η ∈ [0.1,1.0] and the momentum α ∈ [0.1,1.0], whereas SVMs were parameterized with respect to the cost parameter <italic>C</italic> ∈ [0.5,8.0] and kernel specific parameters degree <italic>d</italic> ∈ [1,3], γ ∈ [0.01,0.10] and <italic>coef0</italic> ∈ [0,6].</p>
<fig id="pcbi-1003088-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g003</object-id><label>Figure 3</label><caption>
<title>Workflow for the development of the cascaded machine-learning model.</title>
<p>ANN: feed-forward artificial neural network, SVM: support vector machine. AAFREQ, BINAATYPE, BINPEP, PEPCATS, PPCA and PPCALI correspond to the utilized peptide descriptors (<italic>cf.</italic> Methods). TP, FP, FN and TN correspond to entities of a confusion table with true-positives, false-positives, false-negatives and true-negatives.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g003" position="float" xlink:type="simple"/></fig>
<p>The 12 trained base classifiers were subsequently fed with the same data they were originally trained on to compute the input (<italic>i.e.</italic>, output neuron values from ANN or probability estimates from SVM; from the interval [0,1[) for the second-stage or ‘jury’ ANN classifier. We tested all possible input combinations, resulting in 2<sup>12</sup> = 4096 jury neural networks, where each training instance for a jury ANN had as many dimensions as first stage classification models included. Test data was then presented to the trained first stage models for prediction and the fired output values were propagated to the according trained jury networks, which finally delivered a predicted output class (binder/non-binder; <italic>score threshold</italic> = 0.5). The output class prediction for every test data instance was compared to actual class labels in the test data and summarized in confusion tables (true-positives, false-positives, true-negatives, false-negatives). Confusion tables were then mapped into a single classification performance index (Matthews' correlation coefficient, <italic>MCC</italic>) <xref ref-type="bibr" rid="pcbi.1003088-Matthews1">[27]</xref> and the best performing final jury as a compromise of cross-validated and external set performance was selected and retrained on the entire core data.</p>
<p>The final jury (<xref ref-type="fig" rid="pcbi-1003088-g004">Fig. 4</xref>) model (<italic>MCC</italic><sub>cross-validated</sub> = 0.64, <italic>MCC</italic><sub>external-set</sub> = 0.65) was selected and re-trained on the entire training data set. The obtained <italic>MCC</italic> of 0.64 is well within the quality of current state-of-the-art prediction tools for MHC-I prediction, and with regard to the cross-validated <italic>MCC</italic> suggests that jury over-training/over-fitting was avoided. The prediction method is publicly available at <ext-link ext-link-type="uri" xlink:href="http://modlab-cadd.ethz.ch" xlink:type="simple">http://modlab-cadd.ethz.ch</ext-link> (SLiDER tool, MHC-I version 2012).</p>
<fig id="pcbi-1003088-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g004</object-id><label>Figure 4</label><caption>
<title>Architecture of the best-performing cascaded machine-learning model based on six first stage classifiers originating from three differing descriptor sets and two learning schemes (ANNs, SVMs) and a jury neural network containing three hidden neurons.</title>
<p>The model delivers a prediction score from the interval [0,1[, with high values indicating MHC-I H-2K<sup>b</sup> binding.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s2b">
<title><italic>In silico</italic> MHC-I binding prediction</title>
<p>All octapeptides containing at minimum tripeptide fragments of the positive reference binder SIINFEKL were categorically grouped according to the respective fragment (<xref ref-type="fig" rid="pcbi-1003088-g005">Fig. 5a</xref>). Resulting groups were classified with the best jury model receiving a score between 0 (non-binding) and 1 (binding) regarding MHC-I H-2K<sup>b</sup> binding potential.</p>
<fig id="pcbi-1003088-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g005</object-id><label>Figure 5</label><caption>
<p>(<bold>a</bold>) Distribution of prediction scores for sets of <italic>n</italic> SIINFEKL-fragment containing octapeptides. High scores indicate MHC-I H-2K<sup>b</sup> binding predictions, while lower scores indicate non-binding predictions. Scores were computed with the final jury prediction model. (<bold>b</bold>) Binding of synthesized SIINFEKL-fragments to a MHC-I H-2K<sup>b</sup>:IgG1 fusion protein relative to the average binding of the positive reference (SIINFEKL, 100%) and the unloaded fusion protein (<italic>NoLigand</italic>, 0%). Bars correspond to the arithmetic mean of quadruplicate measurements, with error whiskers depicting the volatility in terms of standard deviation.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g005" position="float" xlink:type="simple"/></fig>
<p>The heptapeptide fragment-containing groups (xIINFEKL, SIINFEKx) comprising 20 peptides each exhibited the highest score distributions (<italic>median values</italic> = 0.99). In contrast, all trimer fragment-containing groups (xxxxxEKL, xxxxFEKx, xxxNFExx, xxINFxxx, xIINxxxx, SIIxxxxx) showed a median at the other end of the prediction range (0 to 0.03) with merely the xxINFxxx group exhibiting values distributed more dispersedly over the entire range [0,1[.</p>
<p>Tetrapeptide fragment-containing groups were categorized into low median groups xxxNFEKx, xxINFExx and SIINxxxx (0.01), and in opposition high median groups xIINFxxx (<italic>median</italic> = 0.75) and xxxxFEKL (<italic>median</italic> = 0.98).</p>
<p>Pentapeptide-fragment containing groups were divided into a high median category containing xxxNFEKL (0.98) as well as SIINFxxx (0.99), and the low median groups xIINFEx (0.16) and xxINFEKx (0.02), while the hexapeptide fragment-containing groups all exhibited high medians: xIINFEKx (0.95), SIINFExx (0.98), and xxINFEKL (0.99).</p>
<p>Examining groups with the same first non-arbitrary (non ‘<italic>x</italic>’) residue from the amino-terminal tail revealed a decrease of median predictions scores, when randomizing an increasing number of amino acids from the carboxy-terminus (<italic>e.g.</italic>, xxINFEKL, xxINFEKx, xxINFExx, xxINFxxx). However, upon randomizing glutamine at position 6 (E to x) this tendency was perturbed by a slight median increase. <italic>Vice versa</italic> held true for the amino-terminus with a similar yet weaker perturbation observed for randomization of the isoleucine at position 3 (<italic>e.g.</italic>, SIINFEKx, xIINFEKx, xxINFEKx, xxxNFEKx, xxxxFEKx). In general, randomizing amino acids at the main anchor positions 5 and 8, which in the case of SIINFEKL comply with the canonical sequence motif, always led to a decrease of the median score. The same held true for randomization of isoleucine at position 2, underlining a similar importance as the canonical anchors.</p>
</sec><sec id="s2c">
<title>Direct-binding experiments</title>
<p>To test the predictions made by our machine-learning model, we synthesized all SIINFEKL fragments and measured MHC-I H-2K<sup>b</sup> binding in a thermal denaturation assay (<xref ref-type="fig" rid="pcbi-1003088-g006">Fig. 6</xref>). The quadruplicate measurements exhibited high consistency between predicted and measured binding, indicated by low standard deviation for all peptide fragments with mean relative binding values greater than zero (<xref ref-type="fig" rid="pcbi-1003088-g005">Fig. 5b</xref>). Based on the unpaired Welch-test <xref ref-type="bibr" rid="pcbi.1003088-Welch1">[28]</xref>, the reference binder SIINFEKL showed a significant increase in binding (100%, <italic>p</italic>&lt;9.9·10<sup>−12</sup>) in comparison to the unloaded MHC-I complex (denoted as <italic>NoLigand</italic> in <xref ref-type="table" rid="pcbi-1003088-t001">Table 1</xref>). The amino-terminal serine-deprived heptapeptide IINFEKL showed the highest remainder of relative binding potential (22%, <italic>p</italic>&lt;9.9·10<sup>−8</sup>). The majority of the remaining fragments showed no significant relative binding. Exceptions include the pentapeptide SIINF (<italic>p</italic>&lt;0.002) and the hexapeptide INFEKL (<italic>p</italic>&lt;0.003) exhibiting 8% respectively 7% relative binding on average, followed by the lowest yet still significant binding of SIINFEK (5%, <italic>p</italic>&lt;0.001) and SIINFE (4%, <italic>p</italic>&lt;0.002).</p>
<fig id="pcbi-1003088-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.g006</object-id><label>Figure 6</label><caption>
<p>(<bold>a</bold>) Melting curves of peptide-MHC-I (H-2K<sup>b</sup>:IgG fusion protein) complexes depicting the normalized fluorescence <italic>F</italic> in relative fluorescence units (RFU) for SIINFEKL and <italic>NoLigand</italic> as positive (red line) and negative (black line) controls, an exemplary epitope fragment (INFE) showing no melting point shift (grey line) and all epitope fragments (IINFEKL, SIINF, INFEKL, SIINFEK, SIINFE) leading to a significant melting point shift (green lines). (<bold>b</bold>) Analogously the first derivative of <italic>F</italic> (d<italic>F</italic>) reveals the melting points as local minima, with <italic>T</italic><sub>m</sub> denoting the presumable MHC-I heavy chain melting point in the absence of peptide ligand <italic>(NoLigand)</italic>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.g006" position="float" xlink:type="simple"/></fig><table-wrap id="pcbi-1003088-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003088.t001</object-id><label>Table 1</label><caption>
<title>Significance analysis examining quadruplicate binding measurements of SIINFEKL fragments.</title>
</caption><alternatives><graphic id="pcbi-1003088-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003088.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Peptide</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic>-value &lt;</td>
<td align="left" rowspan="1" colspan="1">Relative binding <italic>mean</italic> (σ)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">EKL</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FEKL</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FEK</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NFEKL</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NFEK</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NFE</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">INFEKL</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">7% (2%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">INFEK</td>
<td align="left" rowspan="1" colspan="1">0.4</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">INFE</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">INF</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IINFEKL</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">22% (1%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IINFEK</td>
<td align="left" rowspan="1" colspan="1">0.8</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IINFE</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IINF</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IIN</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIINFEK</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">5% (1%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIINFE</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">4% (0%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIINF</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">8% (3%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIIN</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SII</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIINFEKL</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">100% (1%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>NoLigand</italic></td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><p>The null hypothesis for the Welch-test <xref ref-type="bibr" rid="pcbi.1003088-Welch1">[28]</xref> considers the distribution of respective peptide fragments measurements to not be greater than the distribution of <italic>NoLigand</italic> measurements.</p></fn></table-wrap-foot></table-wrap>
<p>It is noteworthy that the pentapeptide SIINF (8%) exhibited significantly higher (<italic>p</italic>&lt;0.037 and <italic>p</italic>&lt;0.014, respectively) binding compared to its elongated derivatives SIINFEK (5%) and SIINFE (4%). A potential explanation is provided by acknowledging glutamate as a suboptimal solution at position 6 (as reflected in the prediction score analysis), thereby neutralizing and even reverting the slightly positive effect on binding by solvent-interacting lysine in position 7. Though, it remains questionable how the pentapeptide SIINF lacking the C-terminal anchor backbone and side-chain interactions is able to induce the formation of the presumably highly flexible MHC binding cavity <xref ref-type="bibr" rid="pcbi.1003088-Murphy1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Madden1">[29]</xref>, especially as the pentapeptide NFEKL containing both main anchors did not exhibit significant binding. Alternatively, analyzing a co-crystal structure of SIINFEKL in the MHC-I H-2K<sup>b</sup> binding cleft (<xref ref-type="fig" rid="pcbi-1003088-g001">Fig. 1</xref>) reveals a compartmentation of the peptide-binding cavity into a small sub-pocket referred to as F-pocket <xref ref-type="bibr" rid="pcbi.1003088-Pease1">[30]</xref>, including the solvent accessible residues 6–7 as well as the C-terminus 8, and a large sub pocket from positions 1 to 5, which is presumably addressed by the SIINF fragment. It is conceivable that the SIINF fragment bound to the MHC protein solely stabilizes the larger sub-pocket by an induced flexible fit. Overall, only fragments exclusively retaining the C- or N-terminus of the fragment source showed significant albeit weak remaining binding potential with at best five-fold lower binding than the positive reference binder. The minimum required length to measure a significant binding potential was provided by the pentapeptide SIINF.</p>
</sec></sec><sec id="s3">
<title>Discussion</title>
<p>The results of this study demonstrate the potential of coupling cascaded machine-learning models for predicting MHC-I antigen presentation to a rapid thermal denaturation assay for validation of direct binding to MHC. Even more, implicating from prediction distributions of SIINFEKL-fragment containing peptides to direct-binding measurements of actual fragments appears to be feasible. The newly established model allows for a fine-grained grasp of sequence motifs, suggesting that sequence length, as defined in previous studies by an optimum of 8–10 amino acids for the H-2K<sup>b</sup> allele, plays a crucial role in the binding mechanism <xref ref-type="bibr" rid="pcbi.1003088-Sesardic1">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Rognan1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Deres1">[32]</xref>. Shorter fragment lengths or randomization of more positions led to lower prediction scores and decreased relative binding with a minimal but still significant effect exhibited by a pentapeptide. The results confirm the importance of serine respectively leucine as N- and C-termini for the example of ovalbumin-derived SIINFEKL <xref ref-type="bibr" rid="pcbi.1003088-Satio1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Shawar1">[34]</xref>, as randomization of these positions concludes to substantially lower scores and lower relative binding measurements (<xref ref-type="fig" rid="pcbi-1003088-g005">Fig. 5</xref>). Comparison of relative binding decrease upon removal of C-terminal leucine reveals this peptide terminus as a dominant contributor even known to allow for longer peptides extending beyond the F-pocket <xref ref-type="bibr" rid="pcbi.1003088-Hrig1">[35]</xref>. The superior importance of the C-terminus is explainable by backbone and aliphatic side chain interactions as an anchor residue.</p>
<p>Concerning the classic canonical sequence motif (<xref ref-type="fig" rid="pcbi-1003088-g001">Fig. 1</xref>) <xref ref-type="bibr" rid="pcbi.1003088-Rammensee3">[10]</xref>, SIINFEKL main anchors (phenylalanine at position 5 and leucine at position 8) were validated by predictions as well as testing, though indication of an aliphatic secondary anchor at position 2 is suggested by observing a reduction of relative binding from IINFEKL (22%) to INFEKL (7%) and concurring predictions. The known secondary anchor at position 3, not fulfilled by the isoleucine of SIINFEKL, is confirmed by this residue's negative effect on binding. Furthermore a distinct negative effect of binding can be concluded for glutamate at position 6 (SIINFEK 5%, SIINFE 4%, SIINF, 8%), as albeit sequence length is decreased, relative binding increased after glutamate removal. Thus, the prediction model successfully captured both negative effects. In general, the model delivers a more fine-grained and differentiated perspective on the entire H-2K<sup>b</sup> binding motif than the classic canonical motif, by not only focusing on anchor residues <xref ref-type="bibr" rid="pcbi.1003088-Corr1">[36]</xref>.</p>
<p>A further prospective analysis of the entire slice-and-diced mouse proteome revealed about 1.75% of octapeptides as confidently (<italic>prediction score</italic> ≥ 0.99) classified MHC-I H-2K<sup>b</sup> binders. For successful rational vaccine designs, machine-learning models with sophisticated meta-learning schemes such as cascaded models should in future be trained for various alleles, rapidly scanning pathogen proteomes for MHC-I ligands. In fact, recent comparison of publicly available prediction tools and community benchmark studies revealed machine-learning models as state-of-the-art for MHC-I and MHC-II prediction, outperforming motif- and matrix-based models <xref ref-type="bibr" rid="pcbi.1003088-Lin1">[37]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Peters2">[38]</xref>. We used a neural network as jury classifier, because ANN have proven to exhibit among the highest prediction accuracies (above 80% for a majority of alleles) <xref ref-type="bibr" rid="pcbi.1003088-Milik1">[39]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-BorrsCuesta1">[40]</xref>, having been successfully applied and experimentally validated for MHC-I <xref ref-type="bibr" rid="pcbi.1003088-Adams1">[41]</xref> MHC-II <xref ref-type="bibr" rid="pcbi.1003088-Brusic1">[42]</xref> ligands. Several prominent MHC prediction tools utilize ANN algorithms, among them NETMHC <xref ref-type="bibr" rid="pcbi.1003088-Lundegaard1">[43]</xref> and MULTIPRED <xref ref-type="bibr" rid="pcbi.1003088-Zhang1">[44]</xref>.</p>
<p>Ensemble models have shown their general usefulness in increasing predictive performance in comparison to their individual base classifiers <xref ref-type="bibr" rid="pcbi.1003088-Rokach1">[45]</xref>, <xref ref-type="bibr" rid="pcbi.1003088-Maclin1">[46]</xref>, with special emphasis on cascaded or stacked generalization architectures exhibiting significantly increased generalization potential <xref ref-type="bibr" rid="pcbi.1003088-Wolpert1">[47]</xref>. As missing out epitopes as a consequence of false-negatives can be detrimental in perspective of reverse vaccinology, <italic>i.e.</italic> scanning and predicting entire pathogenic proteomes, and false-positives undoubtedly lead to increased experimental costs, optimizing the predictive performance with ensemble models can be the critical lever for successful epitope and vaccine design. To best of our knowledge, Hiss <italic>et al.</italic> proposed the only other cascaded model for MHC-I ligand prediction as a scoring function in the scope of agent-based exploration of sequence space <xref ref-type="bibr" rid="pcbi.1003088-Hiss1">[12]</xref>. This model incorporated only three base classifiers with three different descriptors and one learning scheme (ANN) propagating to a single jury neural network. For a recent review on computational resources for MHC ligand prediction, see Koch <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1003088-Koch1">[48]</xref>.</p>
<p>It must be kept in mind though that for some pathogens, an adequate immune response may require activation of not only the cell-mediated MHC-I supported CD8<sup>+</sup> T cell response but also the assistance of MHC-II facilitated CD4<sup>+</sup> T cell responses or antibody-driven humoral responses <xref ref-type="bibr" rid="pcbi.1003088-Delves1">[49]</xref>. Practical and theoretical difficulties when using synthetic linear peptides arise when considering this aspect <xref ref-type="bibr" rid="pcbi.1003088-BenYedidia1">[6]</xref>. In perspective of combatting pathogens or pathogenic components in extracellular spaces, activation of B cells for stimulation of antibody production requires antigen recognition by B cell receptors (BCR). BCRs exclusively specialize in the recognition of antigens located in specific conformations at pathogenic protein or toxin surfaces <xref ref-type="bibr" rid="pcbi.1003088-Parker1">[50]</xref>. These antigens, also referred to as ‘neutralizing epitopes’, can rarely be mimicked by short linear synthetic peptide sequences as those investigated in this project <xref ref-type="bibr" rid="pcbi.1003088-McKeating1">[51]</xref>. Approaches to counteract this issue include usage of appreciably longer or cyclized peptides able to adopt a defined conformational ensemble <xref ref-type="bibr" rid="pcbi.1003088-Madden1">[29]</xref> or structure-based approaches <xref ref-type="bibr" rid="pcbi.1003088-Rognan2">[52]</xref> trying to replace the peptide scaffold. We also wish to point out that the linear peptides focused on in this project can pose putative epitopes for priming of CD8<sup>+</sup> cytotoxic T lymphocytes, while others, subject to MHC-II presentation, may prime CD4<sup>+</sup> helper T cells (T<sub>H</sub>) <xref ref-type="bibr" rid="pcbi.1003088-SmithGarvin1">[53]</xref>. Eventually the primed T cells will differentiate into armed effector and memory cells, providing not only acute but also long-term mediated recruiting of other immune agents by cytokine and chemokine secretion (T<sub>H</sub>) and defense against intracellular pathogen infection by induction of apoptosis <xref ref-type="bibr" rid="pcbi.1003088-Sallusto1">[54]</xref>.</p>
</sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Amino acid descriptors</title>
<p><bold>PEPCATS</bold> is based on the CATS (<italic>Chemically Advanced Template Search</italic>) <xref ref-type="bibr" rid="pcbi.1003088-Schneider1">[55]</xref> topological pharmacophore representation of druglike molecules. Here we employed this concept to encode peptides in terms of their side-chain functionalities <xref ref-type="bibr" rid="pcbi.1003088-Schneider2">[56]</xref>. Instead of typing atoms, up to six different potential pharmacophore features are assigned to the amino acid residues (L: Lipophilic, R: Aromatic, A: Acceptor, D: Donor, P: Positive, N: Negative), which results in 21 different feature pairs (AA, AL, AR, <italic>etc.</italic>). Distances, in terms of sequence position, between two potential pharmacophore points of a respective residue pair are counted and binned for all pairs within a user-defined distance range. We used distances up to seven residue positions, yielding a 21×7 = 147-dimensional length-independent peptide descriptor. The resulting vector elements were scaled by dividing each value by the sum of all occurrences of the same feature pair type <xref ref-type="bibr" rid="pcbi.1003088-Reutlinger1">[57]</xref>.</p>
<p><bold>PPCA</bold> <xref ref-type="bibr" rid="pcbi.1003088-Schneider3">[58]</xref> represents peptides in terms of their physicochemical properties. Each amino acid in a peptide sequence is represented by 19 real-numbered values, which we obtained from a principal component analysis (PCA) performed on 143 acid property scales collected by Tomii and Kanehisa <xref ref-type="bibr" rid="pcbi.1003088-Tomii1">[59]</xref>. The first 19 principle components already account for about 100% of the variance, accordingly this results in a 20-residue×19-score matrix. Raw scores were scaled by unit variance, whereupon each row of the PCA score matrix corresponds to a 19-dimensional description of the respective amino acid.</p>
<p><bold>PPCALI</bold> is a length invariant auto-correlated version of the PPCA descriptor. At first the PPCA vector is calculated and transformed into a matrix column-wise containing the 19 values for each amino acid of a dedicated peptide sequence. Hence this matrix is auto-correlated by summing up the products of matrix row elements with a defined correlation distance for every row, resulting in a total of 19 sums. This is performed for a user-defined correlation distance range (here: zero to seven residue positions). In this case the total dimension of the descriptor is given by concatenating 19 sums from correlation distance 0 to 7 equates to 152 dimensions.</p>
<p><bold>AAFREQ</bold> is a 20-dimensional descriptor containing the amino acid frequencies as integers of a peptide sequence in a fixed order (A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, V).</p>
<p><bold>BINAATYPE</bold> represents each amino acid by six bits, whereas every bit encodes for the presence or absence of a certain pharmacophore feature (Lipophilic, Aromatic, Acceptor, Donor, Positive, Negative) <xref ref-type="bibr" rid="pcbi.1003088-Schneider4">[60]</xref>. BINAATYPE is based on the same pharmacophore types as PEPCATS.</p>
<p><bold>BINPEP</bold> represents the identity of each amino acid by a string of five bits.</p>
</sec><sec id="s4b">
<title>Machine-learning</title>
<p>We used WEKA <xref ref-type="bibr" rid="pcbi.1003088-Hall1">[61]</xref> for ANN and SVM classifier training, with the LIBSVM <xref ref-type="bibr" rid="pcbi.1003088-Chang1">[62]</xref> C-support vector classification (C-SVC) wrapped by the respective Java classes for training the SVM classifiers.</p>
</sec><sec id="s4c">
<title>Thermal denaturation assay</title>
<p>Thermal denaturation studies were conducted using a StepOnePlus real-time PCR system (Applied Biosystems) with MicroAmp optical 96-well plates (Applied Biosystems cat. no. N8010560). Wells were loaded with 10 µl of H-2K<sup>b</sup>:IgG fusion protein solution (protein conc. = 0.5 mg×ml<sup>−1</sup>; BD Biosciences cat. no. 550750) – respectively 10 µl of PBS buffer (pH 7.36) for ligand-only controls – 2 µl of peptide or peptide fragments, 2 µl of 10× SYPRO Orange (SigmaAldrich cat. no. S5692) and 6 µl (8 µl for negative controls) to yield a total volume of 20 µl per well. Final concentrations calculated to 1 µM for H-2K<sup>b</sup>:IgG fusion protein, 100 µM for the peptides/peptide fragments and 1× SYPRO Orange. Fluorescence intensity was measured using the Applied Biosystems ROX preset with respective excitation/emission maxima at 587/607 nm, while heating the wells continuously from 25°C to 99°C with a ramp rate of 1% (temperature increase of 1.5°C per minute). Results were recorded by StepOne 2.2.2 software and analyzed by identifying the local minimum of the derivative of the melting curve for the segment relevant for denaturation of the peptide-binding superdomain (α<sub>1,2</sub>) of the MHC-I heavy chain.</p>
</sec><sec id="s4d">
<title>Peptide synthesis and analytics</title>
<p>DMF (dimethylformamide), DCM (dichlormethane), diisopropylether, piperidine and TIPS (triisopropylsilane) were purchased from Sigma-Aldrich. NMM (4-methylmorpholine) and TFA (2,2,2-trifluoroacetic acid) were acquired from Fisher Scientific; Fmoc-protected Wang-resins, Fmoc-protected amino acids, and HCTU (<italic>O</italic>-(6-chloro-1-hydrocibenzotriazol-1-yl)-1,1,3,3-tetra -methyluronium hexafluorophosphate) were obtained from AAPPTEC. An Overture robotic solid phase peptide synthesizer (Protein Technologies, Tucson, USA) was used to synthesize peptides on a 20 µmol scale utilizing 10-fold excess of Fmoc-protected amino acids (200 mM) relative to the Fmoc-Wang-resin. Deprotection by 20% piperidine in DMF for 2×5 min. Double coupling was performed in a conservative manner of 2×15 min rotations with a ratio of 1∶1∶2 (200 mM amino acid, 200 mM HCTU, 400 mM NMM) in DMF. DMF washing was applied for 5×30 sec after deprotection and double coupling. Automated cleavage was applied for 2 h with 95% vol.+2.5% vol.+2.5% vol. (TFA, H<sub>2</sub>O, TIPS), after multiple washing steps with DCM (3×30 sec). Using ice-cold diisopropylether, the peptides were precipitated from the final TFA-peptide solution and rewashed. All peptide products were analyzed on an LC-20A HPLC instrument (Shimadzu) using an rpC18, 110 Å, 5 µm, 150×3 mm column (Macherey-Nagel), with a linear gradient of 5–70% ACN/H<sub>2</sub>O (0.1% TFA) over 25 min with a flow rate of 0.5 ml×min<sup>−1</sup>; UV-VIS detection at 210 nm. Masses were detected between 300–1500 Da with a Shimadzu LCMS-2020 single-quad mass spectrometer (ESI+). UV<sup>210</sup> purity of all products: &gt;98%. Peptide sequences are denoted with the calculated molecular weight (<italic>mw</italic>, unit: Da), observed retention times (<italic>Rt</italic>, unit: minutes) and masses (<italic>m</italic>+); some peptides exhibited water clusters (*): SII (<italic>mw</italic> = 331.40, <italic>Rt</italic> = 9.87, <italic>m</italic>+ = 332.15, 333.15, 663.4, 664.4), IIN (<italic>mw</italic> = 358.43, <italic>Rt</italic> = 6.86, <italic>m</italic>+ = 359.15, 360.15, 719.40, 717.45, 718.45), INF (<italic>mw</italic> = 392.45, <italic>Rt</italic> = 10.15, <italic>m</italic>+ = 393.15, 394.10, 786.30, 785.4, 1175.75), NFE (<italic>mw</italic> = 408.41, <italic>Rt</italic> = 7.66, <italic>m</italic>+ = 408.10, 409.95, 817.35), FEK (<italic>mw</italic> = 422.48, <italic>Rt</italic> = 6.45, <italic>m</italic>+ = 432.20, 424.20), EKL (<italic>mw</italic> = 388.46, <italic>Rt</italic> = 7.59, <italic>m</italic>+ = 389.15, 390.15, 777.45), SIIN (<italic>mw</italic> = 445.51, <italic>Rt</italic> = 8.86, <italic>m</italic>+ = 446.25, 447.25, 891.55, 892.50), IINF (<italic>mw</italic> = 505.61, <italic>Rt</italic> = 10.36, <italic>m</italic>+ = 527.35*, 528.25*, 529.30*, 957.30*, 958.40*), INFE (<italic>mw</italic> = 521.57, <italic>Rt</italic> = 9.77, <italic>m</italic>+ = 522.25, 523.20, 1043.55, 1044.55, 1045.50), NFEK (<italic>mw</italic> = 536.59, <italic>Rt</italic> = 6.93, m+ = 537.25, 538.25, 539.25), FEKL (<italic>mw</italic> = 534.63, <italic>Rt</italic> = 9.39, <italic>m</italic>+ = 536.35, 537.25, 538.20, 1071.65, 1072.60), SIINF (<italic>mw</italic> = 592.68, <italic>Rt</italic> = 11.99, <italic>m</italic>+ = 593.30, 594.35, 596.25, 1184.85, 1185.75, 1186.70, 1187.70), IINFE (<italic>mw</italic> = 634.72, <italic>Rt</italic> = 10.76, <italic>m</italic>+ = 635.35, 636.30, 637.30, 1269.70, 1270.80), INFEK (<italic>mw</italic> = 649.74, <italic>Rt</italic> = 8.84, <italic>m</italic>+ = 325.75, 650.35, 651.35, 652.35), NFEKL (<italic>mw</italic> = 649.74, <italic>Rt</italic> = 9.59, <italic>m</italic>+ = 650.35, 651.35, 652.30, 1300.85), SIINFE (<italic>mw</italic> = 721.79, <italic>Rt</italic> = 11.5, <italic>m</italic>+ = 722.40, 723.40, 724.30, 1443.9, 1444.90, 1445.90), IINFEK (<italic>mw</italic> = 762.89, <italic>Rt</italic> = 9.77, m+ = 382.35, 763.40, 764.40, 765.40), INFEKL (<italic>mw</italic> = 762.89, <italic>Rt</italic> = 10.84, <italic>m</italic>+ = 382.30, 763.45, 764.4, 957.45, 965.45, 965.45), SIINFEK (<italic>mw</italic> = 849.97, <italic>Rt</italic> = 10.51, <italic>m</italic>+ = 425.80, 850.50, 851.45, 852.45), IINFEKL (<italic>mw</italic> = 876.05, <italic>Rt</italic> = 11.51, <italic>m</italic>+ = 438.95, 876.55, 877.50, 878.50).</p>
</sec></sec></body>
<back>
<ack>
<p>Sarah Haller is thanked for technical assistance.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1003088-Murphy1"><label>1</label>
<mixed-citation publication-type="other" xlink:type="simple">Murphy K (2011) Janeway's Immunobiology. New York: Garland Science. 888 p.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Pashine1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pashine</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Valiante</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Ulmer</surname><given-names>JB</given-names></name> (<year>2005</year>) <article-title>Targeting the innate immune response with improved vaccine adjuvants</article-title>. <source>Nat Med</source> <volume>11</volume>: <fpage>S63</fpage>–<lpage>S68</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Schijns1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schijns</surname><given-names>VE</given-names></name>, <name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name> (<year>2011</year>) <article-title>Trends in vaccine adjuvants</article-title>. <source>Expert Rev Vaccines</source> <volume>10</volume>: <fpage>539</fpage>–<lpage>550</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Clem1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clem</surname><given-names>AS</given-names></name> (<year>2011</year>) <article-title>Fundamentals of vaccine immunology</article-title>. <source>J Global Infect Dis</source> <volume>3</volume>: <fpage>73</fpage>–<lpage>78</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Moisa1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moisa</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kolesanova</surname><given-names>EF</given-names></name> (<year>2010</year>) <article-title>Synthetic peptide vaccines</article-title>. <source>Biokhim Biochem (Mosc)</source> <volume>4</volume>: <fpage>321</fpage>–<lpage>332</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-BenYedidia1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ben-Yedidia</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Arnon</surname><given-names>R</given-names></name> (<year>1997</year>) <article-title>Design of peptide and polypeptide vaccines</article-title>. <source>Curr Opin Biotechnol</source> <volume>8</volume>: <fpage>442</fpage>–<lpage>448</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Sesardic1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sesardic</surname><given-names>D</given-names></name> (<year>1993</year>) <article-title>Synthetic peptide vaccines</article-title>. <source>J Med Microbiol</source> <volume>39</volume>: <fpage>241</fpage>–<lpage>242</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rammensee1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rammensee</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rötschke</surname><given-names>O</given-names></name> (<year>1993</year>) <article-title>MHC molecules as peptide receptors</article-title>. <source>Curr Opin Immunol</source> <volume>5</volume>: <fpage>35</fpage>–<lpage>44</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rammensee2"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rammensee</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rötzschke</surname><given-names>O</given-names></name> (<year>1993</year>) <article-title>Peptides naturally presented by MHC class I molecules</article-title>. <source>Annu Rev Immunol</source> <volume>11</volume>: <fpage>213</fpage>–<lpage>244</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rammensee3"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rammensee</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Bachmann</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Emmerich</surname><given-names>NPN</given-names></name>, <name name-style="western"><surname>Bachor</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Stevanovic</surname><given-names>S</given-names></name> (<year>1999</year>) <article-title>SYFPEITHI: database for MHC ligands and peptide motifs</article-title>. <source>Immunogenetics</source> <volume>50</volume>: <fpage>213</fpage>–<lpage>219</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Peters1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bui</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Frankild</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nielson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lundegaard</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>A community resource benchmarking predictions of peptide binding to MHC-I molecules</article-title>. <source>PLoS Comput Biol</source> <volume>2</volume>: <fpage>e65</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Hiss1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hiss</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Bredenbeck</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Losch</surname><given-names>FO</given-names></name>, <name name-style="western"><surname>Wrede</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Walden</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Design of MHC I stabilizing peptides by agent-based exploration of sequence space</article-title>. <source>Prot Eng Des Sel</source> <volume>20</volume>: <fpage>99</fpage>–<lpage>108</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Bengio1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bengio</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lamblin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Popovici</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Larochelle</surname><given-names>H</given-names></name> (<year>2007</year>) <article-title>Greedy layer-wise training of deep networks</article-title>. <source>Adv Neural Inf Process Syst</source> <volume>19</volume>: <fpage>153</fpage>–<lpage>160</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Vita1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vita</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zarebski</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Greenbaum</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Emami</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hoof</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The Immune Epitope Database 2.0</article-title>. <source>Nucleic Acids Res</source> <volume>38</volume>: <fpage>D854</fpage>–<lpage>D862</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rtzschke1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rötzschke</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Stevanović</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Walden</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>1991</year>) <article-title>Exact prediction of a natural T cell epitope</article-title>. <source>Eur J Immunol</source> <volume>21</volume>: <fpage>2891</fpage>–<lpage>2894</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Khilko1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khilko</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Corr</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Inman</surname><given-names>JK</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity</article-title>. <source>J Biol Chem</source> <volume>268</volume>: <fpage>15425</fpage>–<lpage>15434</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Ddier1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dédier</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reinelt</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rion</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Folkers</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rognan</surname><given-names>D</given-names></name> (<year>2001</year>) <article-title>Use of fluorescence polarization to monitor MHC-peptide interactions in solution</article-title>. <source>J Immunol Methods</source> <volume>255</volume>: <fpage>57</fpage>–<lpage>66</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Senisterra1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Senisterra</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Chau</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Vedadi</surname><given-names>M</given-names></name> (<year>2012</year>) <article-title>Thermal denaturation assays in chemical biology</article-title>. <source>Assay Drug Dev Technol</source> <volume>10</volume>: <fpage>128</fpage>–<lpage>136</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Udaka1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Udaka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wiesmüller</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Kienle</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Walden</surname><given-names>P</given-names></name> (<year>1995</year>) <article-title>Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries</article-title>. <source>J Exp Med</source> <volume>181</volume>: <fpage>2097</fpage>–<lpage>2108</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Khan1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khan</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Biddison</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Wiley</surname><given-names>DC</given-names></name> (<year>2000</year>) <article-title>The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site</article-title>. <source>J Immunol</source> <volume>164</volume>: <fpage>6398</fpage>–<lpage>6405</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-ElManzalawy1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Manzalawy</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Drobbs</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Honavar</surname><given-names>V</given-names></name> (<year>2008</year>) <article-title>On evaluating MHC-II binding peptide prediction methods</article-title>. <source>PLOS One</source> <volume>3</volume>: <fpage>e3268</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Tropsha1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tropsha</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Best practices for QSAR model development, validation, and exploitation</article-title>. <source>Mol Inf</source> <volume>29</volume>: <fpage>476</fpage>–<lpage>488</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Gallinari1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gallinari</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Thiria</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Soulie</surname><given-names>FF</given-names></name> (<year>1988</year>) <article-title>Multilayer perceptrons and data analysis</article-title>. <source>IEEE International Conference on Neural Networks</source> <volume>1</volume>: <fpage>391</fpage>–<lpage>399</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Cortes1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cortes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vapnik</surname><given-names>V</given-names></name> (<year>1995</year>) <article-title>Support-vector networks</article-title>. <source>Machine Learning</source> <volume>20</volume>: <fpage>273</fpage>–<lpage>297</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rumelhart1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rumelhart</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Hinton</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>RJ</given-names></name> (<year>1986</year>) <article-title>Learning representations by back-propagating errors</article-title>. <source>Nature</source> <volume>323</volume>: <fpage>533</fpage>–<lpage>536</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Platt1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Platt</surname><given-names>JC</given-names></name> (<year>1999</year>) <article-title>Using analytic QP and sparseness to speed training of support vector machines</article-title>. <source>Adv Neural Inf Proc Syst</source> <volume>11</volume>: <fpage>557</fpage>–<lpage>563</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Matthews1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matthews</surname><given-names>BW</given-names></name> (<year>1975</year>) <article-title>Comparison of the predicted and observed secondary structure of T4 phage lysozyme</article-title>. <source>Biochim Biophys Acta</source> <volume>405</volume>: <fpage>442</fpage>–<lpage>451</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Welch1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Welch</surname><given-names>BL</given-names></name> (<year>1947</year>) <article-title>The generalization of student's' problem when several different population variances are involved</article-title>. <source>Biometrika</source> <volume>34</volume>: <fpage>28</fpage>–<lpage>35</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Madden1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Madden</surname><given-names>DR</given-names></name> (<year>1995</year>) <article-title>The three-dimensional structure of peptide-MHC complexes</article-title>. <source>Annu Rev Immunol</source> <volume>13</volume>: <fpage>587</fpage>–<lpage>622</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Pease1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pease</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Horton</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Pullen</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Yun</surname><given-names>TJ</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Amino acid changes in the peptide binding site have structural consequences at the surface of class I glycoproteins</article-title>. <source>J Immunol</source> <volume>150</volume>: <fpage>3375</fpage>–<lpage>3381</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rognan1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rognan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Scapozza</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Folkers</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Daser</surname><given-names>A</given-names></name> (<year>1994</year>) <article-title>Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes</article-title>. <source>Biochemistry</source> <volume>33</volume>: <fpage>11476</fpage>–<lpage>11485</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Deres1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deres</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name>, <name name-style="western"><surname>Wiesmüller</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Stevanović</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Greiner</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>1992</year>) <article-title>Preferred size of peptides that bind to H-2 Kb is sequence dependent</article-title>. <source>Eur J Immunol</source> <volume>22</volume>: <fpage>1603</fpage>–<lpage>1608</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Satio1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Satio</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>Y</given-names></name> (<year>1997</year>) <article-title>Contribution of peptide backbone atoms to binding of an antigenic peptide to class I major histocompatibility complex molecules</article-title>. <source>Mol Immunol</source> <volume>34</volume>: <fpage>1133</fpage>–<lpage>1145</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Shawar1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shawar</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Vyas</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rogers</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Rich</surname><given-names>RR</given-names></name> (<year>1993</year>) <article-title>Differential amino-terminal anchors for peptide binding to H-2M3a or H-2Kb and H-2Db1</article-title>. <source>J Immunol</source> <volume>151</volume>: <fpage>201</fpage>–<lpage>210</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Hrig1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hörig</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>ACM</given-names></name>, <name name-style="western"><surname>Papadopoulos</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>DiLorenzo</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Natheson</surname><given-names>SG</given-names></name> (<year>1999</year>) <article-title>Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C-terminus: refinement of inherent MHC class I peptide binding criteria</article-title>. <source>J Immunol</source> <volume>163</volume>: <fpage>4434</fpage>–<lpage>4441</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Corr1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Corr</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Padlan</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Margulies</surname><given-names>DH</given-names></name> (<year>1993</year>) <article-title>H-2Dd exploits a four residue peptide binding motif</article-title>. <source>J Exp Med</source> <volume>178</volume>: <fpage>1877</fpage>–<lpage>1892</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Lin1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tongchusak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reinherz</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Brusic</surname><given-names>V</given-names></name> (<year>2008</year>) <article-title>Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research</article-title>. <source>BMC Immunol</source> <volume>9</volume>: <fpage>8</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Peters2"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bui</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Frankild</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nielson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lundegaard</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>A community resource benchmarking predictions of peptide binding to MHC-I molecules</article-title>. <source>PLoS Comput Biol</source> <volume>2</volume>: <fpage>e65</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Milik1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Milik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sauer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Brunmark</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Vitiello</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Application of an artificial neural network to predict specific class I MHC binding peptide sequences</article-title>. <source>Nat Biotechnol</source> <volume>16</volume>: <fpage>753</fpage>–<lpage>756</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-BorrsCuesta1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Borrás-Cuesta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Golvano</surname><given-names>J</given-names></name>, <name name-style="western"><surname>García-Granero</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sarobe</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Riezu-Boj</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Specific and general HLA-DR binding motifs: comparison of algorithms</article-title>. <source>Human Immunol</source> <volume>61</volume>: <fpage>266</fpage>–<lpage>278</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Adams1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adams</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Koziol</surname><given-names>JA</given-names></name> (<year>1995</year>) <article-title>Prediction of binding to MHC class I molecules</article-title>. <source>J Immunol Methods</source> <volume>185</volume>: <fpage>181</fpage>–<lpage>190</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Brusic1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brusic</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rudy</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Honeyman</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hammer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Harrison</surname><given-names>L</given-names></name> (<year>1998</year>) <article-title>Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network</article-title>. <source>Bioinformatics</source> <volume>14</volume>: <fpage>121</fpage>–<lpage>130</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Lundegaard1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lundegaard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lamberth</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Harndahl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Buus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lund</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11</article-title>. <source>Nucleic Acids Res</source> <volume>36</volume>: <fpage>W509</fpage>–<lpage>W512</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Zhang1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Srinivasan</surname><given-names>KN</given-names></name>, <name name-style="western"><surname>August</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Brusic</surname><given-names>V</given-names></name> (<year>2005</year>) <article-title>Multipred: a computational system for prediction of promiscuous HLA binding peptides</article-title>. <source>Nucleic Acids Res</source> <volume>33</volume>: <fpage>W172</fpage>–<lpage>W179</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rokach1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rokach</surname><given-names>L</given-names></name> (<year>2010</year>) <article-title>Ensemble-based classifiers</article-title>. <source>Artif Intell Rev</source> <volume>33</volume>: <fpage>1</fpage>–<lpage>39</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Maclin1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maclin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Opitz</surname><given-names>D</given-names></name> (<year>1999</year>) <article-title>Popular ensemble methods: An empirical study</article-title>. <source>J Artif Intell Res</source> <volume>11</volume>: <fpage>169</fpage>–<lpage>198</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Wolpert1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wolpert</surname><given-names>DH</given-names></name> (<year>1992</year>) <article-title>Stacked generalization</article-title>. <source>Neural Networks</source> <volume>5</volume>: <fpage>241</fpage>–<lpage>259</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Koch1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koch</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Pillong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hiss</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name> (<year>2013</year>) <article-title>Computational resources for MHC ligand identification</article-title>. <source>Mol Inf</source> <volume>32</volume>: <fpage>326</fpage>–<lpage>336</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Delves1"><label>49</label>
<mixed-citation publication-type="other" xlink:type="simple">Delves PJ, Martin SJ, Burton DR, Roitt IM (2011) Roitt's Essential Immunology. New York: Wiley-Blackwell. 546 p.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Parker1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parker</surname><given-names>DC</given-names></name> (<year>1993</year>) <article-title>T cell-dependent B cell activation</article-title>. <source>Annu Rev Immunol</source> <volume>11</volume>: <fpage>331</fpage>–<lpage>360</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-McKeating1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McKeating</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Shotton</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cordell</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balfe</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120</article-title>. <source>J Virol</source> <volume>67</volume>: <fpage>4932</fpage>–<lpage>4944</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Rognan2"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rognan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Reddehase</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Koszinowski</surname><given-names>UH</given-names></name>, <name name-style="western"><surname>Folkers</surname><given-names>G</given-names></name> (<year>2004</year>) <article-title>Molecular modeling of an antigenic complex between a viral peptide and a class I major histocompatibility glycoprotein</article-title>. <source>Proteins</source> <volume>13</volume>: <fpage>70</fpage>–<lpage>85</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-SmithGarvin1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith-Garvin</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Koretzky</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>MS</given-names></name> (<year>2009</year>) <article-title>T cell activation</article-title>. <source>Annu Rev Immunol</source> <volume>27</volume>: <fpage>591</fpage>–<lpage>619</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Sallusto1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sallusto</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Geginat</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name> (<year>2004</year>) <article-title>Central memory and effector memory T cell subsets: function, generation, and maintenance</article-title>. <source>Annu Rev Immunol</source> <volume>22</volume>: <fpage>745</fpage>–<lpage>763</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Schneider1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Neidhart</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Giller</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schmid</surname><given-names>G</given-names></name> (<year>1999</year>) <article-title>“Scaffold-hopping” by topological pharmacophore search: A contribution to virtual screening</article-title>. <source>Angew Chem Int Ed</source> <volume>38</volume>: <fpage>2894</fpage>–<lpage>2896</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Schneider2"><label>56</label>
<mixed-citation publication-type="other" xlink:type="simple">Schneider G, Broger C (1999) Visualization of protein sequence space by self-organizing neural networks - Classification of protein targeting signals. In: Wagner E, Normann J, Greppin H, Hackstein JHP, Herrmann RG <etal>et al</etal>.., editors. From Symbiosis to Eukaryotism - Endocytobiology VII. Geneva: Geneva University Press. pp. 589–602.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Reutlinger1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reutlinger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Reker</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Todoroff</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Chemically advanced template search (CATS) for scaffold-hopping and prospective target prediction for ‘orphan’ molecules</article-title>. <source>Mol Inf</source> <volume>32</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Schneider3"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wrede</surname><given-names>P</given-names></name> (<year>1998</year>) <article-title>Artificial neural networks for computer-based molecular design</article-title>. <source>Prog Biophys Mol Biol</source> <volume>70</volume>: <fpage>175</fpage>–<lpage>222</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Tomii1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomii</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name> (<year>1996</year>) <article-title>Analysis of amino acid indices and mutation matrices for sequence comparison and structure prediction of proteins</article-title>. <source>Protein Eng</source> <volume>9</volume>: <fpage>27</fpage>–<lpage>36</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Schneider4"><label>60</label>
<mixed-citation publication-type="other" xlink:type="simple">Schneider G, Baringhaus KH (2008) Molecular Design: Concepts and Applications. Weinheim, New York: Wiley-VCH. 262 p.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Hall1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hall</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Frank</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pfahringer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Reutemann</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The WEKA data mining software: an update</article-title>. <source>ACM SIGKDD Explorations Newsletter</source> <volume>11</volume>: <fpage>10</fpage>–<lpage>18</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Chang1"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>CJ</given-names></name> (<year>2011</year>) <article-title>LIBSVM: a library for support vector machines</article-title>. <source>ACM Trans Intell Syst Technol</source> <volume>2</volume>: <fpage>1</fpage>–<lpage>27</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Berman1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berman</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Westbrook</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Gilliland</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>TN</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>The Protein Data Bank</article-title>. <source>Nucleic Acids Res</source> <volume>28</volume>: <fpage>235</fpage>–<lpage>242</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003088-Fremont1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fremont</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Stura</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Matsumura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>IA</given-names></name> (<year>1995</year>) <article-title>Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>92</volume>: <fpage>2479</fpage>–<lpage>2483</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>